[New oral anticoagulants (NOAC) in stroke treatment]

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• New oral anticoagulants (NOAC) have been available since 2011 for preventing cardioembolic ischemic strokes.
• NOACs are indicated for patients diagnosed with non-valvular atrial fibrillation.
• Despite ongoing debate in Germany, neurological and cardiological societies advocate for NOACs over vitamin K antagonists due to a superior benefit-to-risk ratio.

Purpose of the Study:

• To review the current landscape of new oral anticoagulants (NOACs) for stroke prevention.
• To highlight the comparative advantages and limitations of NOACs in clinical practice.
• To emphasize the need for individualized patient selection for NOAC therapy.

Main Methods:

• Literature review of existing studies on new oral anticoagulants (NOACs).
• Analysis of recommendations from neurological and cardiological societies.
• Examination of antidote availability and ongoing research for factor Xa inhibitors.

Main Results:

• New oral anticoagulants (NOACs) demonstrate a lower risk of intracranial hemorrhage compared to vitamin K antagonists.
• A specific antidote is available only for dabigatran, a direct thrombin inhibitor.
• Antidotes for factor Xa inhibitors are currently under investigation in clinical trials.
• No direct head-to-head studies comparing different NOACs are available.

Conclusions:

• The decision to use a specific new oral anticoagulant (NOAC) should be individualized.
• Treatment selection should consider patient characteristics, comorbidities, and available scientific data from NOAC trials.
• While NOACs offer benefits, the lack of head-to-head trials means no single NOAC can be deemed superior.